Cell MedX Corp
Cell MedX Corp., a biotech company, discovers, develops, and commercializes therapeutic and non-therapeutic products for patients with diabetes, Parkinson's disease, high blood pressure, neuropathy, and kidney functions in the United States. The company develops and manufactures eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and eBalance Home System fo… Read more
Cell MedX Corp (CMXC) - Total Assets
Latest total assets as of November 2024: $38.35K USD
Based on the latest financial reports, Cell MedX Corp (CMXC) holds total assets worth $38.35K USD as of November 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Cell MedX Corp - Total Assets Trend (2013–2024)
This chart illustrates how Cell MedX Corp’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Cell MedX Corp - Asset Composition Analysis
Current Asset Composition (May 2024)
Cell MedX Corp's total assets of $38.35K consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 94.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Cell MedX Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cell MedX Corp's current assets represent 100.0% of total assets in 2024, unchanged from 100.0% in 2013.
- Cash Position: Cash and equivalents constituted 94.1% of total assets in 2024, down from 100.0% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Cell MedX Corp Competitors by Total Assets
Key competitors of Cell MedX Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
Cell MedX Corp - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Cell MedX Corp generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Cell MedX Corp is currently not profitable relative to its asset base.
Cell MedX Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.06 | 0.01 | 0.13 |
| Quick Ratio | 0.06 | 0.01 | 0.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-626.93K | $ -2.53 Million | $ -1.47 Million |
Cell MedX Corp - Advanced Valuation Insights
This section examines the relationship between Cell MedX Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 587.59 |
| Asset Growth Rate (YoY) | -55.3% |
| Total Assets | $46.12K |
| Market Capitalization | $27.10 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Cell MedX Corp's assets at a significant premium ( 587.59x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Cell MedX Corp's assets decreased by 55.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cell MedX Corp (2013–2024)
The table below shows the annual total assets of Cell MedX Corp from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-05-31 | $46.12K | -55.34% |
| 2023-05-31 | $103.27K | +149.78% |
| 2022-05-31 | $41.34K | -20.86% |
| 2021-05-31 | $52.24K | -67.18% |
| 2020-05-31 | $159.18K | -16.46% |
| 2019-05-31 | $190.54K | +321.00% |
| 2018-05-31 | $45.26K | -84.59% |
| 2017-05-31 | $293.73K | +9.22% |
| 2016-05-31 | $268.93K | +477.54% |
| 2015-05-31 | $46.56K | +3777.10% |
| 2014-05-31 | $1.20K | -89.06% |
| 2013-05-31 | $10.98K | -- |